kindolor

Kindolor is a novel, non-opiate, non-addicting small molecule developed to treat chronic pain and diabetic neuropathic pain. It was designed using a network pharmacology approach to simultaneously target multiple key nodes in the peripheral nociceptive sensory pathway. Specifically, Kindolor inhibits voltage-sensitive sodium channels Nav1.7 and Nav1.8, blocks NMDA receptors (particularly those containing the NR2B subunit), and acts as an agonist of the delta opioid receptor. The compound is engineered to act primarily in the periphery with minimal penetration into the central nervous system, aiming to reduce side effects associated with CNS-active analgesics and avoid addiction potential seen with opioids[1][3][4][5][6].

Brand names

kindolor

Other names

kindolor tosylateLohocla 201Lohocla201Lohocla-201